RxDoctor Payments Data

Ronald Richardson

Optometrist · McAllen, TXNPI 1568431047

Payments from drug & device makers

$2,841in general payments, 2019–2025

Across 44 payments — averaging $64.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Coopervision Inc.$287
  • Aerie Pharmaceuticals, Inc.$227
  • AbbVie$223
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$190
  • Oyster Point Pharma, Inc.$120
  • plus $437 from 5 others

What the payments were for

  • Travel & lodging$66123%
  • Food & beverage$2,18077%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,841 in reported general payments places this provider in the 80th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$98,615
Medicare patients
385
Services billed
1,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine83$54,912
SimbrinzaBrinzolamide/Brimonidine Tart118$26,841
TyrvayaVarenicline Tartrate12$13,451
LumiganBimatoprost17$11,885
Latanoprost1,068$11,411
Cyclosporine28$9,757
XiidraLifitegrast11$8,964
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol52$7,564
RhopressaNetarsudil Mesylate15$7,448
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha488$5,782
Alphagan PBrimonidine Tartrate12$4,869
Brimonidine Tartrate45$3,106
Travoprost20$2,895
Prednisolone Acetate57$1,643
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat152$1,640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$223$71,666112 claims
AlconSimbrinza$1,356$26,841118 claims
Oyster Point Pharma, Inc.Tyrvaya$120$13,45112 claims
Aerie Pharmaceuticals, Inc.Rhopressa$227$7,44815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,315 optometrist providers in Texas.

Other optometrist in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →